Aim: Risk factors for cisplatin-induced nephrotoxicity (CIN) vary by population. This study aimed to assess risk factors for CIN in patients with gynecological cancer. Methods: Patients who underwent cisplatin-based chemotherapy for gynecological cancer between January 2009 and December 2015 at Aichi Medical University School of Medicine were included in this study. CIN was defined according to the 'risk, injury, failure, loss, and end-stage kidney disease' (RIFLE) criteria and classified as either risk (Class R) or injury (Class I). Analyses were performed using univariate and multivariate logistic regression models. Results: Among 112 patients enrolled, 30 had CIN. Multivariate analysis revealed that hydration with magnesium (odds ratio [OR], 0.223), history of cisplatin use (OR, 4.420), and hypoalbuminemia (OR, 4.170) were risk factors for Class R, and that frequency of cisplatin administration (OR, 5.620) and hydration with magnesium (OR, 0.216) were risk factors for Class I. Conclusion: This study confirmed that hydration without magnesium, history of cisplatin use, frequency of cisplatin administration, and hypoalbuminemia are significant risk factors for CIN.
Introduction
Cisplatin has been widely used for the clinical treatment of various solid tumors, although it causes nephrotoxicity as a major dose-limiting side-effect. The frequency of cisplatin-induced nephrotoxicity (CIN) is reported to be 28-42%, 1,2 with some patients exhibiting an irreversible decrease in glomerular filtration. 3 Cisplatin therapy cannot be continued if patients develop severe CIN, and subsequent chemotherapy with other anticancer drugs may be challenging given their limited availability.
Hydration is the standard preventive approach against CIN, but some patients nevertheless present clinical symptoms of renal dysfunction. 3, 4 Although a number of pharmacologic agents (e.g., amifostine, sodium thiosulfate, and magnesium) have been shown to decrease nephrotoxicity, 5 none play an established role. Therefore, the assessment of risks among patients with CIN is of clinical importance, since the development of CIN or a worsening of its symptoms can be prevented. In addition, careful consideration should be given to avoid coadministration of other potentially nephrotoxic agents and, if necessary, cisplatin should be switched with other platinum-containing drugs. Known risk factors for CIN include high cisplatin dose, concomitant use of other nephrotoxic drugs, female sex, older age, smoking, and hypoalbuminemia. 2, 5, 6 The dose of cisplatin used for gynecological cancer is usually 60 mg/m 2 or less, which is lower compared to other cancer regimens. Moreover, patients with gynecological cancer tend to be younger compared to those with other cancers, and present with characteristics different from other cancer patients (e.g., cardiac disease and smoking). Risk factors and odds ratios for CIN vary due to differences in populations, 2, 7, 8 and no study to date has assessed risk factors for CIN associated with gynecological cancer. Thus, a detailed assessment of CIN among patients with gynecological cancer may help to reduce the incidence of CIN in this population. To this end, we retrospectively investigated risk factors for CIN in patients with gynecological cancer at Aichi Medical University School of Medicine.
Methods

Eligibility criteria
We 
Hydration protocol
Patients receiving cisplatin adhered to the prescribed hydration protocol of our hospital. The hydration protocol was drawn up as follows: 2500 mL of fluids (lactate Ringer's solution) to be infused prior to the administration of cisplatin, and 500 mL, 1000 mL, and 1000 mL of fluid (lactate Ringer's solution) to be infused for 3 days after the administration of cisplatin. We established the hydration protocol that mannitol and diuretic were not used from the beginning; these drugs were used if the patient's urine flow was below 100 mL/h for 2 days following cisplatin administration despite additional infusion solution. Furthermore, magnesium sulfate was added from 2012 in this protocol (day 1, 15 mEq; day 2-3, 5 mEq).
Collection of data
All data were obtained from electronic charts. The following data were collected for each patient: age, body surface area, body mass index, gynecological carcinoma tumor type, disease stage, PS, chemotherapy regimen, prior treatment, cisplatin dose, cumulative dose of cisplatin per square meter, frequency of cisplatin administration, history of cisplatin use in previous chemotherapy regimens, baseline renal function (serum creatinine, eGFR), and hydration with or without magnesium. Information on regular administration of non-steroidal anti-inflammatory drugs (NSAID), hypertension, history of cisplatin use, diabetes mellitus, and hypoalbuminemia was collected in terms of their presence or absence. CIN was evaluated according to the 'risk, injury, failure, loss, and end-stage kidney disease' (RIFLE) criteria, 9 which are widely used to assess acute nephrotoxicity. The RIFLE criteria define 'risk' (Class R) as a proportional increase in serum creatinine of more than 50% or a decrease in eGFR of more than 25% relative to baseline after cisplatin administration, and 'injury' (Class I) as a proportional increase in serum creatinine of more than 100% or a decrease in eGFR of more than 50% relative to baseline after cisplatin administration. Class I includes Class R. The calculation for eGFR was as follows: eGFR = 194 × Scr À 1.094 × age À 0.287 × 0.739. We collected the worst level for each renal function parameter throughout the course of treatment in all patients, and classified CIN into Class R or Class I according the RIFLE criteria, in reference to previous reports.
10,11
Statistical analyses
Categorical variables were compared using Fisher's exact test. Univariate logistic regression was used to identify factors associated with the incidence of CIN (Class R or I). In addition, multivariate analysis was performed to determine independent risk factors; covariates that were significant in univariate analysis were incorporated into multivariate analysis. Stepwise selection, including all significant parameters, was performed to select more reliable predictive independent parameters. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), a graphical user interface for R (The R Foundation for Statistical Computing). Specifically, it is a modified version of R commander designed to include statistical functions frequently used in biostatistics. All reported P-values were two-sided, and P < 0.05 was considered statistically significant. Y. Yamamoto et al. 
Results
Patient characteristics
We analyzed 112 patients with gynecological cancer who had received cisplatin during the study period. Among these, 30 patients developed CIN (Class R, n = 30; Class I, n = 10). Patient characteristics are summarized in Table 1 . The study population included younger women at a median age of 58 years, of whom approximately 95%
were PS 0-1; the number of patients with diabetes mellitus and hypertension was low and there were no patients with cardiac disease. BMI, body mass index; CI, confidence interval; CIN, cisplatin-induced nephrotoxicity; eGFR, estimated glomerular filtration rate; NSAID, non-steroidal anti-inflammatory drugs; PS, performance status.
cisplatin due to cancer recurrence or metastasis during the survey period and we defined these patients as having a history of cisplatin use. Tables 2 and 3 show the relation between each factor determined by univariate analysis. In Class R, univariate analysis revealed hydration with magnesium, history of cisplatin use, and hypoalbuminemia to be significant risk factors for CIN. Multivariate analysis using these factors showed that hydration with magnesium (odds ratio [OR], 0.223; P < 0.01), history of cisplatin use (OR, 4.420; P = 0.02), and hypoalbuminemia (OR, 4.170; P < 0.01) were independent risk factors for Class R CIN (Table 4) . In Class I, univariate analysis revealed that frequency of cisplatin administration, hydration with magnesium, and hypoalbuminemia were significant risk factors for CIN. There were significantly high correlations between Class I and frequency of cisplatin administration (OR, 5.620; P = 0.04) and hydration with magnesium (OR, 0.216; P = 0.04).
Univariate analysis and multivariate analysis
Discussion
We found that hypoalbuminemia, history of cisplatin use, and hydration without magnesium were risk factors for Class R CIN, whereas hydration without magnesium and frequency of cisplatin administration were risk factors for Class I CIN. In this study, hydration with magnesium was associated with a decreased risk of CIN in both Class R and Class I. We previously reported that hydration with magnesium provided protective effects against CIN. 10, 11 In the present study, multivariate analysis revealed that hydration with magnesium also has a nephroprotective effect. Hypoalbuminemia was associated with CIN (Class R) in this study, which is consistent with previous reports, 2, 5 although the mechanism is unclear. Cisplatin is a highly protein-bound drug, and therefore, the plasma concentration of unbound cisplatin may increase in patients with hypoalbuminemia, causing enhanced renal toxicity. CIN is related to the peak plasma concentration and/or the area under the plasma concentration-time curve of non-protein-bound cisplatin. 12 In addition, patients with hypoalbuminemia might be at risk for malnourishment and poor PS. Based on these results, we believe that careful attention should be paid to CIN in patients with hypoalbuminemia.
Our results showed that frequency of cisplatin administration is a risk factor for Class I CIN, and that a history of cisplatin use is a risk factor for Class R CIN. These results are in line with previous studies reporting frequency of administration and cumulative dose of cisplatin as risk factors for CIN. 5 Patients who respond to initial platinum-based therapy and have a long interval of time to recurrence are recommended to undergo retreatment with platinum-containing drugs, including cisplatin, in gynecological cancer. Therefore, there are likely more patients who had been readministered cisplatin in this particular population compared to those with other cancers. We speculate that a history of cisplatin use is a risk factor that contributes to the development of CIN not only because it is associated with an increased frequency of administration and the cumulative dose of cisplatin, but also due to the irreversible nature of CIN. This report is the first to suggest that focus should be placed on the relationship between history of cisplatin use and CIN. Cumulative dose of cisplatin was not shown to affect CIN, perhaps due to the small number of patients in this study.
Limitations of this study include the retrospective design and small sample size. Further prospective studies with a larger sample size are needed. The study population included patients who were younger and showed good performance, and are thus unlikely to be affected by hypertension, diabetes mellitus, or cardiovascular disease. Consequently, we could not examine their associations. Further clinical studies will be needed to address this issue. In this study, our findings revealed a significant association of CIN with hypoalbuminemia, history of cisplatin use, and hydration without magnesium in Class R CIN; and hydration without magnesium and frequency of cisplatin administration in Class I CIN. Thus, the substitution of the other platinum drugs for cisplatin might be considered for patients who require readministration of cisplatin and those with hypoalbuminemia. In addition, hydration with magnesium might reduce the risk of CIN from our results as well as previous studies 8, 10, 11 ; therefore, we recommend administering hydration supplemented with magnesium for patients receiving cisplatin-based chemotherapy.
